We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Enhertu Outperforms Kadcyla in Metastatic HER2+ Breast Cancer
Enhertu Outperforms Kadcyla in Metastatic HER2+ Breast Cancer
The AstraZeneca and Daiichi Sankyo HER2-targeting drug/antibody conjugate garnered headlines at the European Society for medical Oncology meeting last week, posting wins in metastatic HER2+ breast cancer, advanced gastric cancer, and non-small cell lung cancer.
